EGFR and non-small cell lung carcinoma: Therefore, the development of a new generation of EGFR-TKI and cMET inhibitors represents a critical strategy for overcoming EGFR-TKI resistance in NSCLC.11, 12, 13, 14, 15, 16, 17, 18, 19 Unfortunately, EGFR-independent mechanisms of acquired resistance to AZD9291, a third-generation TKI, have already been reported in EGFR-E790M-positive NSCLC patients.20